Cell and Gene Therapy: Curative Modalities and Their Economics

Introduction

Cell and gene therapies represent a paradigm shift in medicine: instead of treating disease chronically (pills every day, infusions every month), these modalities aim to cure disease in a single treatment. This curative potential creates enormous clinical value but introduces unique economic challenges that do not exist in traditional pharmaceutical valuation. How do you price a one-time cure? How do you model revenue for a product that "consumes" its market? How do you value a manufacturing process that costs $95,000 per patient to execute? These questions make cell and gene therapy among the most intellectually complex areas in healthcare banking.

Cell Therapy (CAR-T)

CAR-T (chimeric antigen receptor T-cell) therapy involves extracting a patient's own T-cells (white blood cells), genetically engineering them in a laboratory to express a chimeric antigen receptor that recognizes a specific protein on cancer cells, expanding the modified cells to billions of copies in a manufacturing facility, and infusing them back into the patient. The engineered T-cells then circulate through the body, find cancer cells expressing the target protein, and kill them.

Approved CAR-T therapies (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti) are priced at $373,000-$475,000 per treatment and are approved primarily for blood cancers (lymphoma, leukemia, multiple myeloma). The total CAR-T market generated approximately $4-5 billion in 2024 revenue and is growing as approvals expand to earlier lines of therapy (treating patients sooner rather than as a last resort).

Autologous vs. Allogeneic Cell Therapy

Autologous cell therapy uses the patient's own cells, requiring individual manufacturing for each patient. This creates a complex, personalized supply chain with manufacturing COGS of approximately $95,000 per patient, 3-4 week turnaround times (during which the patient's cancer may progress), and inherent variability (each patient's cells behave differently in manufacturing, leading to occasional manufacturing failures). Allogeneic (off-the-shelf) cell therapy uses donor cells that can be manufactured in advance at scale and stored in inventory, similar to traditional drug manufacturing. Allogeneic approaches promise dramatically lower COGS (potentially $10,000-20,000 per dose), faster treatment delivery (days instead of weeks), and consistent product quality. However, allogeneic therapies face additional scientific challenges: graft-versus-host disease risk (the donor cells may attack the patient's healthy tissue), shorter cell persistence (the patient's immune system may reject the donor cells), and gene editing requirements (to make the donor cells compatible). The transition from autologous to allogeneic manufacturing would transform cell therapy economics from a personalized manufacturing model to a scalable inventory model.

Gene Therapy

Gene therapies deliver functional copies of genes (or gene-editing tools like CRISPR) to correct or compensate for genetic defects. Unlike cell therapy, gene therapies typically use viral vectors (AAV or lentivirus) to deliver the genetic material directly to the patient's cells in vivo and do not require extraction of the patient's cells.

Approved gene therapies include Zolgensma (spinal muscular atrophy, priced at $2.1 million), Hemgenix (hemophilia B, priced at $3.5 million, the most expensive drug ever approved), Casgevy (sickle cell disease, the first CRISPR-based therapy, priced at approximately $2.2 million), and Elevidys (Duchenne muscular dystrophy, priced at $3.2 million). The pricing reflects the one-time curative nature: these therapies aim to eliminate the need for lifelong chronic treatment.

AAV (Adeno-Associated Virus) Vector

The most commonly used delivery vehicle for gene therapy. AAV vectors are engineered viruses that have been stripped of their ability to cause disease and loaded with the therapeutic gene. Different AAV serotypes (AAV1, AAV5, AAV8, AAV9, etc.) have natural affinity for different tissues: AAV9 crosses the blood-brain barrier and targets the central nervous system (used in Zolgensma), AAV5 targets the liver (used in Hemgenix), and AAV8 also targets the liver for different applications. The choice of serotype determines which diseases a gene therapy can treat, and the development of new engineered AAV capsids (with improved tissue targeting and reduced immune response) is a major area of R&D investment. A key limitation is that patients who have pre-existing antibodies to a specific AAV serotype (from natural viral exposure) may be ineligible for gene therapies using that serotype, reducing the addressable patient population by 20-40% depending on the serotype.

This one-time treatment model creates several valuation complications:

Front-loaded revenue. When a curative therapy launches, there is a backlog of existing patients ("prevalent pool") who can be treated immediately. Revenue peaks in years 1-3 as the prevalent pool is treated, then declines to a steady state reflecting only newly diagnosed (incident) patients. This front-loading makes revenue highly sensitive to launch execution, physician awareness, patient identification infrastructure, and insurance coverage decisions. A delay in payer coverage by even 6-12 months can significantly reduce the capture of the prevalent pool.

Manufacturing constraints. Autologous cell therapies can only treat one patient at a time per manufacturing slot. A single manufacturing facility might have capacity for 2,000-4,000 patients per year, and building new facilities takes 2-3 years and costs $100-300 million. Manufacturing capacity limitations cap the number of patients that can be treated per year, creating a bottleneck that may prevent the company from capturing the full prevalent pool quickly and stretching the revenue curve over more years.

Payer pushback and access challenges. One-time treatments costing $1-3.5 million create massive per-patient costs for insurers, even though the total lifetime cost may be lower than chronic treatment. A hemophilia patient on factor replacement therapy costs $300,000-500,000 per year for life; Hemgenix at $3.5 million is cost-effective over a 10-15 year horizon but requires the payer to absorb the entire cost upfront. Payers have developed outcomes-based contracts (paying only if the therapy works), installment payment models (spreading the cost over 3-5 years), and value-based arrangements to manage the upfront financial impact. These innovative payment models are still evolving, and payer access remains a significant uncertainty in gene therapy revenue projections.

The next article covers emerging modalities including mRNA, RNAi, radioligands, and protein degraders.